Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

18 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differentially expressed genes after miRNA or siRNA transfection in human cancer cell lines

ABSTRACT: To identify differentially expressed genes by anti cancer treatments (microRNAs or siRNAs) in human cancer, several cell lines (bladder cancer, prostate cancer, hypopharyngeal cancer and lung squamous cell carcinoma) were subjected to Agilent whole genome microarrays. Human cancer cell lines (BOY, BOY-GFP, T24, PC3, FaDU, LNCap, DU145, EBC-1 and SK-MES-1 ) were treated with miRNAs (miR-218, miR-24, miR-144, miR-451, miR-221, miR-222, miR-224, miR-1, miR-133a and miR-452), siRNAs (si-LASP1 and si-FOXM1).

ORGANISM(S): Homo sapiens

SUBMITTER: Naohiko Seki

PROVIDER: E-GEOD-56243 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Differentially expressed genes after miRNA or siRNA transfection in human cancer cell lines II

Project description:To identify differentially expressed genes by anti cancer treatments (microRNAs or siRNAs) in human cancer, several cell lines (pancreatic cancer, esophageal cancer, bladder cancer, prostate cancer, renal cell carcinoma and lung squamous cell carcinoma) were subjected to Agilent whole genome microarrays. Human cell lines (Panc-1, sw1990, TE8, TE9, A549, MRC-5, BOY, T24, PC3, C4-2, 786-O, A-498 and EBC-1) were treated with miRNAs (miR-375, miR-29a, miR-26a, miR-145-5p, miR-145-3p, miR-218, miR-320a), siRNAs (si-MMP11, si-LAMP1, si-LOXL2, si-PLOD2, si-UHRF1, and si-FOXM1).

2016-04-13 | E-GEOD-77790 | biostudies-arrayexpress

Differentially expressed genes after miRNA or siRNA transfection in human cancer cell lines (II)

Project description:To identify differentially expressed genes by anti cancer treatments (microRNAs or siRNAs) in human cancer, several cell lines (bladder cancer, prostate cancer, renal cell carcinoma, oral squamous cell carcinoma and lung squamous cell carcinoma) were subjected to Agilent whole genome microarrays. Human cancer cell lines (SAS, HSC3, BOY, T24, PC3, PC3M, DU145, C4-2, 786-O, A-498 and EBC-1) were treated with miRNAs (miR-205, miR-29a, miR-144-3p, miR-144-5p, miR-451, miR-210, miR-145-5p, miR-145-3p, miR-23b cluster, miR-221, miR-222 and miR-223), siRNAs (si-GOLM1, si-HMGB3, si-CENPF, si-LOXL2, si-TMEM184B and si-CORO1C).

2016-04-13 | E-GEOD-66498 | biostudies-arrayexpress

Differentially expressed genes after miRNA or siRNA transfection in human cancer cell lines Panc-1, FaDu and PC3

Project description:To identify differentially expressed genes by anti cancer treatments (microRNAs or siRNAs) in human cancer, several cell lines (pancreatic cancer, hypopharyngeal squamous cell carcinoma and prostate cancer) were subjected to Agilent whole genome microarrays. Human cell lines (Panc-1, FaDu and PC3) were treated with miRNAs (miR99a-5p, miR-99a-3p, miR-100-3p, miR-150-5p and miR-150-3p), siRNAs (si-FOXQ1).

2016-08-16 | E-GEOD-85614 | biostudies-arrayexpress

Identification of target genes of cancer-related microRNAs in human cancer

Project description:To identify target genes of cancer-related microRNAs in human cancer, several cell lines (bladder cancer, prostate cancer, renal cell carcinoma, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma) were subjected to Agilent whole genome microarrays. Human cancer cell lines (BOY, T24, A498, 786-O, caki-1, LNCap, PC3, TE2, T.Tn, FaDu, SAS, HSC3, and IMC-3) were transfected with miRNAs (miR-375, miR-145, miR-200a, miR-200b, miR-200c, miR-141, miR-429, miR-138, miR-218, miR-874, miR-31, miR-222, miR-1285, and miR-206) or siRNAs (si-FOXA1_1, si-FOXA1_3, and si-TAGLN2). The miRNA-transfected human cancer cell lines were compared to control cell lines.

2012-11-12 | E-GEOD-37119 | biostudies-arrayexpress

Differentially expressed genes by anti tumor treatment in human cancer cell lines

Project description:To identify differentially expressed genes by anti cancer treatments (microRNAs, siRNAs and chemical compounds) in human cancer, several cell lines (prostate cancer, renal cell carcinoma and head and neck squamous cell carcinoma) were subjected to Agilent whole genome microarrays. Human cancer cell lines (PC3, DU145, LNCap, A498, 786-O, FaDu and SAS) were treated with miRNAs (miR-145, miR-375, miR-23b, miR-24, miR-27b and miR-29a), siRNAs (si-CAV2, si-LAMB3 and si-GOLM1) and chemical compunds (genistein, wogonin and CXCL10).

2013-09-25 | E-GEOD-47657 | biostudies-arrayexpress

Analysis of differentially expressed miRNA in cisplatin-resistant FaDu cell

Project description:Cisplatin is a common chemotherapeutic drug for hypopharyngeal cancer. But cisplatin-resistance of hypopharyngeal cancer is rarely explored. We cultured hypopharyngeal cancer cell (FaDu) and induced its cisplatin-resistant cell (FaDu/DDP4). The resistance index (RI) of FaDu/DDP4 was 2.828. Then we tested the differentially expressed genes (DEGs) between FaDu and FaDu/DDP4. DEGs contain 2388 lncRNAs, 1932 circRNAs, 745 mRNAs and 202 miRNAs. We used Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyzed the DEGs. The differentially expressed 745 mRNAs were classified into 3 domains and 47 secondary GO terms. In KEGG pathway enrichment, “TNF signaling pathway”, “IL-17 signaling pathway” and “JAK-STAT signaling pathway” have greater enrich factors. And we drew the ceRNA networks of DEGs. 52 lncRNAs, 148 circRNAs, 155 mRNAs and 18 miRNAs were selected to draw the network. We noticed several potential targets (as miR-197-5p, miR-6808-5p, APOE, MMP1, S100A9 and CYP24A1). At last, we chose 8 miRNAs and 6 mRNAs for qRT-PCR to verify our microarray. In them, miR-197-5p, miR-6808-5p, APOE, MMP1, S100A9 and CYP24A1 might be potential genes inducing resistance.

2021-06-02 | GSE167398 | GEO

Analysis of differentially expressed lncRNA, circRNA and mRNA between FaDu and cisplatin-resistant FaDu cell

2021-06-02 | GSE167396 | GEO

Identification of target genes of tumor suppressor microRNAs in human cancer

Project description:To identify target genes of tumor suppressive microRNAs in human cancer, several cell lines (bladder cancer, prostate cancer, renal cell carcinoma, and head and neck squamous cell carcinoma) were subjected to Agilent whole genome microarrays. miR-517a, miR-218, miR-145, miR-1 and miR-874 function as tumor suppressors. Human cancer cell lines (BOY, T24, A498, PC3, DU145, FaDu, SAS, HSC3, IMC3) were transfected with miRNAs (miR-517a, miR-218, miR-145, miR-1, miR-874). The miRNA-transfected human cancer cell lines were compared to control cell lines.

2012-02-09 | E-GEOD-24782 | biostudies-arrayexpress

Regulation of downstream pathway of NSUN2 knockdown in hypopharyngeal carcinoma FaDu cell line

Project description:It has been confirmed that nsun2 promotes cell proliferation and migration in hypopharyngeal cancer cell lines, but the pathway of nsun2 in hypopharyngeal cancer cell lines is poorly understood. We constructed stable cell lines by knocking down nsun2 to find the key genes of downstream pathway, and compared them with normal FaDu cell lines.It has been confirmed that nsun2 promotes cell proliferation and migration in FaDu cell line, but the pathway of nsun2 in FaDu cell line is poorly understood. We constructed stable cell lines by knocking down nsun2 to find the key genes of downstream pathway, compared them with normal FaDu cell lines.

2024-01-15 | GSE164886 | GEO

Transcriptome drift of FADU after expression of HIF-1a, Twist1 or Bmi1

Project description:Expression of HIF-1a or Twist1 or Bmi1 in human hypopharyngeal cancer cell line FADU results in the drift of transcriptome profile from an epithelial cell-like signature to a mesenchymal stem cell-like signature. Stable transfection of pHA-HIF1a(dODD), pFLAG-Twist1 or pcDNA3-Bmi1 in FADU cell and analyzed the transcriptome by cDNA microarray. FADU transfected with pcDNA3.1 empty vector was used as a control of experiment.

2010-12-10 | E-GEOD-19406 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data